과체중 또는 비만이 있는 건강한 성인 일본인 참가자를 대상으로 ABBV-295의 피하 주사에 대한 이상 반응, 내약성 및 약동학을 평가하는 연구.

Inclusion Criteria:

• Japanese participant must be first-or second-or third-generation Japanese of full Japanese parentage.

  1. First-generation participants must have two parents and four grandparents of full Japanese descent.
  2. Second-or third-generation participants born outside of Japan must have two parents and four grandparents of full Japanese descent.

• BMI is ≥ 25.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

Exclusion Criteria:

• Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
• HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
• Participant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-(GLP-1) agonists, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine-based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.